Introduction: Catheter-related bloodstream infection (CRBSI) is a serious complication in patients receiving home parenteral nutrition (HPN). Antibiotic lock therapy (ALT) and ethanol lock therapy (ELT) can be used to prevent CRBSI episodes in high-risk patients.

Methods: Following institutional review board approval, all patients enrolled in the Mayo Clinic HPN program from January 1, 2006, to December 31, 2013, with catheter locking were eligible to be included. Patients without research authorization and <18 years old at the initiation of HPN were excluded. Total number of infections before and after ALT or ELT were estimated in all patients.

Results: A total of 63 patients were enrolled during the study period. Of 59 eligible patients, 29 (49%) were female, and 30 (51%) were male. The median duration of HPN was 3.66 (interquartile range, 0.75-8.19) years. The mean age ± SD at initiation of HPN was 49.89 ± 14.07 years. A total of 51 patients were instilled with ALT, and 8 patients were instilled with ELT during their course of HPN. A total of 313 CRBSI episodes occurred in these patients, 264 before locking and 49 after locking ( P < .001). Rate of infection per 1000 catheter days was 10.97 ± 25.92 before locking and 1.09 ± 2.53 after locking ( P < .001).

Discussion: The major findings of the present study reveal that ALT or ELT can reduce the overall rate of infections per 1000 catheter days. ALT or ELT can be used in appropriate clinical setting for patients receiving HPN.

Download full-text PDF

Source
http://dx.doi.org/10.1177/0148607115604118DOI Listing

Publication Analysis

Top Keywords

catheter-related bloodstream
8
bloodstream infection
8
patients receiving
8
receiving parenteral
8
parenteral nutrition
8
lock therapy
8
prevention subsequent
4
subsequent catheter-related
4
infection catheter
4
catheter locks
4

Similar Publications

Background: Oritavancin (ORT) is a new single-dose lipoglycopeptide showing activity against staphylococci and vancomycin-resistant enterococci. However, there is no data regarding its potential use as a catheter lock solution are scarce. We constructed an model to analyze the efficacy and stability of an ORT lock solution against the biofilm of staphylococci and enterococci over 7 days at 37 °C.

View Article and Find Full Text PDF

catheter-related bloodstream infections (CRBSIs) are an increasing concern in Japanese hospitals. Although their clinical characteristics have been explored, the genetic relationships and virulence profiles of isolates from CRBSIs remain understudied. Here, using advanced genomic techniques, we investigated the genetic diversity, phylogenetic relationships, and virulence profiles of isolates from patients with bloodstream infections.

View Article and Find Full Text PDF

Comparison of taurolidine with 4% ethylenediaminetetraacetic acid on antimicrobial lock effectiveness: An experimental study.

JPEN J Parenter Enteral Nutr

January 2025

3rd Department of Internal Medicine-Metabolic Care and Gerontology, University Hospital and Medical Faculty in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic.

Background: Antimicrobial lock therapy is recommended for preventing and treating catheter-related bloodstream infections, but different solutions have uncertain efficacy.

Methods: Two locks, 1.35% taurolidine and 4% ethylenediaminetetraacetic acid (EDTA), were tested on Staphylococcus epidermidis, Staphylococcus aureus, methicillin-resistant S.

View Article and Find Full Text PDF

Timely and effective rescue of critically ill children no longer solely relies on advanced medical technology; vascular access plays a pivotal role. Best practice recommendations for nursing in vascular access are critical for ICU patients. However, clear guidelines for the maintenance of external infusion connection devices remain lacking.

View Article and Find Full Text PDF

To assess the clinical usefulness of teicoplanin optimized by means of a therapeutic drug monitoring (TDM)-guided approach for treating secondary bloodstream infections (BSIs) caused by . Hospitalized patients having in the period 1 March 2021-31 October 2024 a documented BSI caused by glycopeptide-susceptible being treated with teicoplanin as definitive targeted therapy optimized by means of a real-time TDM-guided expert clinical pharmacological advice (ECPA) program were retrospectively included. Teicoplanin trough concentrations (C) ranging from 20 to 30 mg/L were defined as the desired target of efficacy based on international guidelines.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!